Research Progress on Luteinizing Hormone and Polycystic Ovary Syndrome
DOI:
https://doi.org/10.53469/jcmp.2024.06(10).23Keywords:
Assisted reproductive technology, Luteinizing hormone, Polycystic ovary syndrome, Follicle stimulating hormoneAbstract
Polycystic ovary syndrome is a common endocrine disease in women of childbearing age, with an incidence of about 6% to 10%, which is the main cause of anovulatory infertility. With the development of assisted reproductive technology, up to 60% of patients with polycystic ovary syndrome need to be pregnant successfully through in vitro fertilization and embryo transfer. Ovarian controlled ovulation induction is an important process in assisted reproductive therapy. Luteinizing hormone plays an important role in the development and maturation of follicles in the ovary, and high levels of luteinizing hormone have a negative effect on pregnancy outcome. at present, it is still controversial that the appropriate level of luteinizing hormone will improve the pregnancy outcome, and the mechanism of how luteinizing hormone affects the pregnancy outcome is still unclear. This article will mainly review the above two aspects in order to provide reference for clinical research in the future.
References
Physiology, Luteinizing Hormone (StatPearls [Internet]) 2022; PMID: 30969514
Sinchak, K, Mohr, MA, Micevych, PE. Hypothalamic Astrocyte Development and Physiology for Neuroprogesterone Induction of the Luteinizing Hormone Surge. Front Endocrinol (Lausanne). 2020; 11 420.
Bosch, E, Alviggi, C, Lispi, M, et al. Reduced FSH and LH action: implications for medically assisted reproduction. HUM REPROD. 2021; 36 (6): 1469-1480.
Cadagan, D, Khan, R, Amer, S. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. REPROD BIOL. 2016; 16 (1): 53-60.
Schniewind, HA, Sattler, LM, Haudum, CW, et al. Autoimmunity to the Follicle-Stimulating Hormone Receptor (FSHR) and Luteinizing Hormone Receptor (LHR) in Polycystic Ovarian Syndrome. Int J Mol Sci. 2021; 22 (24):
McCartney, CR, Campbell, RE, Marshall, JC, et al. The role of gonadotropin-releasing hormone neurons in polycystic ovary syndrome. J NEUROENDOCRINOL. 2022; 34 (5): e13093.
Emanuel, RHK, Roberts, J, Docherty, PD, et al. A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions. Front Endocrinol (Lausanne). 2022; 13 1017468.
Al Kafhage, FA, Abbas, AN, Al-Masaoodi, RA, et al. The relationship between hormonal levels and hematological parameters in cystic ovarian syndrome. J Med Life. 2023; 16 (6): 937-940.
Deswal, R, Narwal, V, Dang, A, et al. The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. J Hum Reprod Sci. 2020; 13 (4): 261-271
Zarei, E, Binabaj, MM, Zadeh, FM, et al. Kisspeptin levels in relation to sex hormone profile among PCOS patients. IRISH J MED SCI. 2021; 191 (4): 1711-1716.
Tang, R, Ding, X, Zhu, J. Kisspeptin and Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2019; 10 298.
Liu, Z, Wang, KH. Effect of basal luteinizing hormone (bLH) level on in vitro fertilization/intra-cytoplasmic injections (IVF/ICSI) outcomes in polycystic ovarian syndrome (PCOS) patients. BMC Pregnancy Childbirth. 2023; 23 (1): 618.
Xia, Q, Xie, L, Wu, Q, et al. Elevated baseline LH/FSH ratio is associated with poor ovulatory response but better clinical pregnancy and live birth in Chinese women with PCOS after ovulation induction. Heliyon. 2023; 9 (1): e13024.
Wesevich, VG, Seckin, SI, Kelk, DA, et al. hMG addition affects the change in progesterone level during IVF stimulation and LBR: a retrospective cohort study. Reprod Biol Endocrinol. 2023; 21 (1): 117.
Liang, Y, Hou, X, Chen, H, et al. Assisted Reproductive Technology Outcomes in Women with Normal Ovarian Response Receiving Recombinant Luteinizing Hormone/Human Menopausal Gonadotropin: An Observational Study. Int J Womens Health. 2024; 16 1103-1111.
Tesarik, J, Conde-López, C, Galán-Lázaro, M, et al. Luteal Phase in Assisted Reproductive Technology. Front Reprod Health. 2020; 2 595183.
Emanuel, RHK, Roberts, J, Docherty, PD, et al. A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions. Front Endocrinol (Lausanne). 2022; 13 1017468.
Longobardi, S, Klinger, FG, Zheng, W, et al. Gonadotropin Activity during Early Folliculogenesis and Implications for Polycystic Ovarian Syndrome and Premature Ovarian Insufficiency: A Narrative Review. Int J Mol Sci. 2024; 25 (14):
Homburg, R, Crawford, G. The role of AMH in anovulation associated with PCOS: a hypothesis. HUM REPROD. 2014; 29 (6): 1117-21.
Emanuel, RHK, Roberts, J, Docherty, PD, et al. A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions. Front Endocrinol (Lausanne). 2022; 13 1017468.
Liu, S, Lv, YS, Han, S, et al. A novel GnRH antagonist protocol based on LH levels versus traditional flexible GnRH antagonist protocol in PCOS patients undergoing in vitro fertilization: study protocol for a randomized controlled, non-inferiority trial. Trials. 2022; 23 (1): 654.
Wang, J, Ding, J, Qu, B, et al. Does Serum LH Level Influence IVF Outcomes in Women with PCOS Undergoing GnRH-Antagonist Stimulation: A Novel Indicator. J Clin Med. 2022; 11 (16)
Wang, L, Wang, J, Hu, YQ, et al. [Effects of time of recombinant luteinized hormone supplementation on pregnancy outcomes of women with advanced reproductive age during follicular-phase long protocol]. Zhonghua Fu Chan Ke Za Zhi. 2022; 57 (10): 758-766.
Zhai, J, Zhang, J, He, J, et al. Live Birth Outcomes for PCOS Patients Under the Follicular-Phase Long-Acting GnRH Agonist Protocol or Antagonist Protocol - A Retrospective Chinese Cohort. J Multidiscip Healthc. 2023; 16 2781-2792.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jianlei Li, Wenyi Wang, Danli Zhang, Lifei Zhou, Ruoyue Cui, Pingping Zhang, Yali Li
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
